We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
SPEVIGO (Boehringer Ingelheim Pty Ltd)
Product name
SPEVIGO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
226 (255 working days)
Active ingredients
spesolimab
Registration type
NCE/NBE
Indication
SPEVIGO is indicated for the treatment of flares in adult patients with generalised pustular psoriasis.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.